Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

February 26, 2015
Laurence Albiges, MD
Laurence Albiges, MD

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Albiges says obesity and being overweight are established risk factors to develop RCC. Conversely, patients that are overweight typically have smaller tumors and have better outcomes.

This study looked at approximately 4000 patients with mRCC treated with systemic therapy. It was confirmed that patients with high BMI were more likely to have a longer overall survival, longer time to treatment failure, and better tumor shrinkage, compared with patients with low or normal BMI.

<<<

View more from the 2015 GU Cancer Symposium


x